152 related articles for article (PubMed ID: 31413609)
1. Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain.
Sánchez-Cenizo L; Aller J; Martínez-Sesmero JM; Mir N; Peral C; Rubio-Rodríguez D; Rubio-Terrés C
Clinicoecon Outcomes Res; 2019; 11():465-475. PubMed ID: 31413609
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
[No Abstract] [Full Text] [Related]
3. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
7. How to Position Pasireotide LAR Treatment in Acromegaly.
Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
[TBL] [Abstract][Full Text] [Related]
8. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant.
Chiloiro S; Giampietro A; Visconti F; Rossi L; Donfrancesco F; Fleseriu CM; Mirra F; Pontecorvi A; Giustina A; Fleseriu M; De Marinis L; Bianchi A
Endocrine; 2021 Sep; 73(3):658-666. PubMed ID: 33907985
[TBL] [Abstract][Full Text] [Related]
9. Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.
Zhang JJ; Nellesen D; Ludlam WH; Neary MP
J Med Econ; 2016; 19(4):374-85. PubMed ID: 26629745
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly.
Grasso LFS; Auriemma RS; Pivonello R; Colao A
Expert Rev Endocrinol Metab; 2017 Jan; 12(1):73-85. PubMed ID: 30058878
[TBL] [Abstract][Full Text] [Related]
12. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
13. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
14. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels.
Droste M; Domberg J; Buchfelder M; Mann K; Schwanke A; Stalla G; Strasburger CJ
Eur J Endocrinol; 2014 Jul; 171(1):59-68. PubMed ID: 24913198
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for acromegaly: future role for pasireotide?
Ben-Shlomo A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):35-41. PubMed ID: 25732640
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
[TBL] [Abstract][Full Text] [Related]
17. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
[TBL] [Abstract][Full Text] [Related]
18. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.
Brue T; Lindberg A; Jan van der Lely A; Akerblad AC; Koltowska-Häggström M; Gomez R; Droste M; Hey-Hadavi J; Strasburger CJ; Camacho-Hübner C
Endocrine; 2019 Mar; 63(3):563-572. PubMed ID: 30474822
[TBL] [Abstract][Full Text] [Related]
19. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
